Selected aspects of human pathology, clinical oncology and epidemiology. Faculty of Medicine, Oslo 2005. 34. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998, 82: 2256–2261.PubMedCrossRef 35. Neves AF, Araújo TG, Biase WK, Meola J, Alcântara TM, Freitas DG, Goulart

LR: Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem 2008, 41: 1191–1198.PubMedCrossRef 36. Balk SP, Ko YJ, Bubley GJ: Biology of Prostate-specific antigen. Journal of Clinical Oncology 2003, 21: 383–391.PubMedCrossRef 37. Panobinostat molecular weight Colombatti M, Grasso S, Porzia A, Fracasso G, Scupoli MT, Cingarlini S, Poffe O, Naim HY, Heine M, Tridente G, Mainiero F, Ramarli D: The Prostate Specific Membrane Antigen

Regulates the Expression of IL-6 and CCL5 in Prostate Tumour Cells by Activating the MAPK Pathways. Plos One 2009, 4: e4608.PubMedCrossRef 38. Paliouras M, Diamandis EP: An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. Biol Chem 2008, 389: 773–780.PubMedCrossRef 39. Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO: 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. Prostate 2008, 68: 773–783.PubMedCrossRef 40. Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH: Docetaxel down-regulates the expression of androgen receptor and prostate-specific ICG-001 solubility dmso antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009, 69: 1579–1585.PubMedCrossRef 41. Denmeade

SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT: Dissociation between androgen responsiveness for malignant growth vs expression of prostate specific differentiation buy Docetaxel markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003, 54: 249–257.PubMedCrossRef 42. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996, 48: 326–334.PubMedCrossRef 43. Gustavsson H, Welén K, Damber JE: Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 2005, 62: 364–373.PubMedCrossRef 44. Tsui P, Rubenstein M, Guinan P: Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis. J Biomed Biotechnol 2005, 2005: 287–290.PubMedCrossRef 45. Puhr M, Santer FR, Neuwirt H, Marcias G, Hobisch A, Culig Z: SOCS-3 antagonises the proliferative and migratory effects of FGF-1 2 in prostate cancer by inhibition of p44/p42 MAPK signaling. Endocr Relat Cancer 2010, 17: 525–53.